HHV Biotech
HHV Biotech is committed to tackling biofilm-related disorders, including chronic and acute infections, and antimicrobial resistance at its root cause. They use proprietary compounds with proven anti-biofilm properties and are involved in innovative research and development to combat antimicrobial resistance and biofilm-associated infections.
Industries
biotechnology
medical
therapeutics
Nr. of Employees
small (1-50)
Products
Lead anti-biofilm small-molecule clinical candidate
A clinical-stage small-molecule candidate developed to prevent or disrupt bacterial biofilms; GMP-manufactured material has been produced in quantities sufficient for IND-enabling studies and initiation of human clinical development.
Lead anti-biofilm small-molecule clinical candidate
A clinical-stage small-molecule candidate developed to prevent or disrupt bacterial biofilms; GMP-manufactured material has been produced in quantities sufficient for IND-enabling studies and initiation of human clinical development.
Services
Partnerships and collaborative development
Engagement with external partners and consortia to co-develop anti-biofilm and AMR-related programs.
Partnerships and collaborative development
Engagement with external partners and consortia to co-develop anti-biofilm and AMR-related programs.
Expertise Areas
- Anti-biofilm therapeutics
- Quorum sensing modulation
- Antimicrobial resistance (AMR) research
- Preclinical development and IND preparation
Key Technologies
- Anti-biofilm small molecules
- Quorum sensing inhibitors
- GMP drug-substance manufacturing
- Purification and downstream processing